. 2023 Jul 13;14:1235285. doi: 10.3389/fphar.2023.1235285

TABLE 1.

The effect of MK-2206 on the efficacy of mitoxantrone, SN-38 and topotecan in cancer cells overexpressing the ABCG2 transporter.

Treatments	IC₅₀ ± SD (μM)^$
Treatments	H460	H460/MX20	S1	S1-M1-80
Mitoxantrone + vehicle	0.0106 ± 0.008	0.703 ± 0.374^###	0.123 ± 0.023	7.901 ± 0.917^###
+ 0.3 μM MK-2206		0.048 ± 0.022^***		0.493 ± 0.180^***
+ 1 μM MK-2206		0.009 ± 0.002^***		0.092 ± 0.022^***
+ 3 μM Ko-143		0.059 ± 0.025^***		0.113 ± 0.136^***
SN-38 + vehicle	0.069 ± 0.017	1.917 ± 0.562^###	0.097 ± 0.023	5.187 ± 2.722^###
+ 0.3 μM MK-2206		0.225 ± 0.042^***		2.309 ± 0.341^**
+ 1 μM MK-2206		0.081 ± 0.021^***		0.136 ± 0.131^***
+ 3 μM Ko-143		0.147 ± 0.095^***		0.096 ± 0.025^***
Topotecan + vehicle	0.081 ± 0.041	2.498 ± 0.043^###	0.481 ± 0.122	21.46 ± 9.603^##
+ 0.3 μM MK-2206		0.257 ± 0.054^***		7.663 ± 6.434^*
+ 1 μM MK-2206		0.051 ± 0.049^***		0.407 ± 0.441^**
+ 3 μM Ko-143		0.077 ± 0.071^**		0.591 ± 0.176^**

^$ Each value represents the mean IC50 value ± the S.D. (calculated by GraphPad 7.00), based on three independent experiments.

^##, ^###, p < 0.01, 0.001 vs. anticancer drug + vehicle in H460 or S1 cell lines; ^*, ^**, ^***, p < 0.05, 0.01, 0.001 vs. anticancer drug + vehicle in H460/MX20 or S1-M1-80 cell lines.